SC 13G 1 p23-0317sc13g.htm CARDIFF ONCOLOGY, INC.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No.  )*
 

Cardiff Oncology, Inc.

(Name of Issuer)
 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)
 

14147L108

(CUSIP Number)
 

**

(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 9 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**The reporting person are eligible to file on Schedule 13G and have elected to switch from the Schedule 13D originally filed on July 2, 2020 back to Schedule 13G.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 14147L10813GPage 2 of 9 Pages

 

1

NAME OF REPORTING PERSON

 

Acorn Bioventures, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ☒

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.38%

12

TYPE OF REPORTING PERSON

PN

         

 

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

 

CUSIP No. 14147L10813GPage 3 of 9 Pages

 

1

NAME OF REPORTING PERSON

 

Acorn Capital Advisors GP, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ☒

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.38%

12

TYPE OF REPORTING PERSON

OO

         

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

 

CUSIP No. 14147L10813GPage 4 of 9 Pages

 

1

NAME OF REPORTING PERSON

 

Anders Hove

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ☒

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,043,173 (including 1,711,666 shares of Common Stock issuable upon exercise of warrants)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.38%

12

TYPE OF REPORTING PERSON

IN

         

* Includes (i) 482,160 Series M Warrants and (ii) 1,229,506 Series N Warrants, which are exercisable for shares of Common Stock.

 

 

CUSIP No. 14147L10813GPage 5 of 9 Pages

 

Item 1(a). Name of Issuer.
   
  Cardiff Oncology, Inc. (the "Issuer")

 

Item 1(b). Address of Issuer's Principal Executive Offices.
   
 

11055 Flintkote Avenue

San Diego, California 92121

 

Item 2(a). Name of Person Filing.
   
  This statement is filed by:
   
  (i) Acorn Bioventures, L.P. (“Acorn”);
  (ii) Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn; and
  (iii) Anders Hove (“Hove”), who is the manager of Acorn GP.

 

  The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  
   
  The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

 

Item 2(b). Address of Principal Business Office.
   
  The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170
   
Item 2(c). Place of Organization.
   
  Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Hove is a citizen of the United States of America.

 

Item 2(d). Title of Class of Securities.
   
  Common stock, $0.0001 par value per share (the "Common Stock")

 

Item 2(e). CUSIP Number.
   
  14147L108

 

CUSIP No. 14147L10813GPage 6 of 9 Pages

 

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

  (g) o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h) ¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

 

  (i) ¨

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution:________________________________________

 

Item 4. Ownership.
   
 

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

 

The percentages set forth herein are calculated based on 44,677,169 shares of the Company’s common stock, par value $0.0001 per share outstanding as of October 27, 2022, as set forth in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 and filed with the Commission on November 3, 2022, and assumes the exercise of the reported warrants.

 

Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn.

 

Hove, in his capacity as the manager of Acorn GP, may be deemed to beneficially own the shares beneficially owned by Acorn.

 

CUSIP No. 14147L10813GPage 7 of 9 Pages

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  Not applicable.

 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
   
  Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   
  Not applicable.

 

Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.

 

Item 9. Notice of Dissolution of Group.
   
  Not applicable.

 

Item 10. Certification.
   
  By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

CUSIP No. 14147L10813GPage 8 of 9 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:  January 26, 2023  
  ACORN BIOVENTURES, L.P.
  By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner
  By:  

/s/ Anders Hove

  Name:  Anders Hove   
  Title:    Manager
   
   
  ACORN CAPITAL ADVISORS GP, LLC
  By:  

/s/ Anders Hove

  Name:  Anders Hove   
  Title:    Manager
   
   
  ANDERS HOVE
 

/s/ Anders Hove

   
   
   

 

 

CUSIP No. 14147L10813GPage 9 of 9 Pages

Exhibit A

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date:  January 26, 2023  
  ACORN BIOVENTURES, L.P.
  By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner
  By:  

/s/ Anders Hove

  Name:  Anders Hove   
  Title:    Manager
   
   
  ACORN CAPITAL ADVISORS GP, LLC
  By:  

/s/ Anders Hove

  Name:  Anders Hove   
  Title:    Manager
   
   
  ANDERS HOVE
 

/s/ Anders Hove